Adverse events180

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 180

Type	Event	Organ system	Group	Affected	At risk
other	Mucositis	Gastrointestinal disorders	Arm A, Cohort 1: Nab-Sirolimus in Patients With Recurrent High Grade Glioma	4	7
other	Mucositis	Gastrointestinal disorders	Arm A, Cohort 2: Nab-Sirolimus + Temozolomide in Patients With Recurrent High Grade Glioma	5	6
other	Mucositis	Gastrointestinal disorders	Arm A, Cohort 3: Nab-Sirolimus + Bevacizumab in Patients With Recurrent High Grade Glioma	2	9
other	Mucositis	Gastrointestinal disorders	Arm A, Cohort 4: Nab-Sirolimus + Lomustine in Patients With Recurrent High Grade Glioma	2	4
other	Mucositis	Gastrointestinal disorders	Arm A, Cohort 5: Nab-Sirolimus + Marizomib in Patients With Recurrent High Grade Glioma	1	10
other	Mucositis	Gastrointestinal disorders	Arm B: Nab-Sirolimus + Temozolomide + Radiotherapy in Patients With Newly Diagnosed Glioblastoma	14	26
other	Diarrhea	Gastrointestinal disorders	Arm A, Cohort 1: Nab-Sirolimus in Patients With Recurrent High Grade Glioma	3	7
other	Diarrhea	Gastrointestinal disorders	Arm A, Cohort 2: Nab-Sirolimus + Temozolomide in Patients With Recurrent High Grade Glioma	1	6
other	Diarrhea	Gastrointestinal disorders	Arm A, Cohort 3: Nab-Sirolimus + Bevacizumab in Patients With Recurrent High Grade Glioma	1	9
other	Diarrhea	Gastrointestinal disorders	Arm A, Cohort 4: Nab-Sirolimus + Lomustine in Patients With Recurrent High Grade Glioma	1	4
other	Diarrhea	Gastrointestinal disorders	Arm A, Cohort 5: Nab-Sirolimus + Marizomib in Patients With Recurrent High Grade Glioma	1	10
other	Diarrhea	Gastrointestinal disorders	Arm B: Nab-Sirolimus + Temozolomide + Radiotherapy in Patients With Newly Diagnosed Glioblastoma	2	26
other	Nausea	Gastrointestinal disorders	Arm A, Cohort 1: Nab-Sirolimus in Patients With Recurrent High Grade Glioma	1	7
other	Nausea	Gastrointestinal disorders	Arm A, Cohort 2: Nab-Sirolimus + Temozolomide in Patients With Recurrent High Grade Glioma	2	6
other	Nausea	Gastrointestinal disorders	Arm A, Cohort 3: Nab-Sirolimus + Bevacizumab in Patients With Recurrent High Grade Glioma	0	9
other	Nausea	Gastrointestinal disorders	Arm A, Cohort 4: Nab-Sirolimus + Lomustine in Patients With Recurrent High Grade Glioma	1	4
other	Nausea	Gastrointestinal disorders	Arm A, Cohort 5: Nab-Sirolimus + Marizomib in Patients With Recurrent High Grade Glioma	2	10
other	Nausea	Gastrointestinal disorders	Arm B: Nab-Sirolimus + Temozolomide + Radiotherapy in Patients With Newly Diagnosed Glioblastoma	3	26
other	Vomiting	Gastrointestinal disorders	Arm A, Cohort 1: Nab-Sirolimus in Patients With Recurrent High Grade Glioma	0	7
other	Vomiting	Gastrointestinal disorders	Arm A, Cohort 2: Nab-Sirolimus + Temozolomide in Patients With Recurrent High Grade Glioma	2	6

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03463265/events

API reference For AI assistants

Adverse events180

Sources 3

Read this list from software.